Study on plasma resistin as a biomarker for preliminary screening of sarcopenia in elderly adults

doi:10.16150/j.1671-2870.2026.02.012

Abstract

Abstract:

Objective To investigate the clinical correlation between plasma resistin levels and sarcopenia in the elderly, and evaluate its preliminary screening value for sarcopenia in the elderly, providing a reference for early identification and intervention of sarcopenia in the elderly. Methods A case-control study design was used. A total of 363 elderly patients who met the inclusion and exclusion criteria in the Department of Geriatrics of the First Hospital of Lanzhou University from December 2021 to December 2023 were enrolled as research subjects. The diagnosis of sarcopenia was based on the 2019 consensus of the Asian Working Group for Sarcopenia. Patients were divided into sarcopenia group and non-sarcopenia group, according to the presence of sarcopenia, and the differences in plasma resistin levels between the two groups were compared. Pearson correlation analysis was conducted to analyze the correlation between plasma resistin levels and sarcopenia indicators, such as grip strength, five-time sit-to-stand test time, gait speed, and appendicular skeletal muscle mass index (ASMI). Logistic regression analysis was used to analyze the independent correlation between plasma resistin levels and sarcopenia in the elderly, and the receiver operating characteristic (ROC) curve was used to evaluate its performance in identifying elderly individuals at high risk for sarcopenia. Results A total of 363 elderly patients were included, including the sarcopenia group (178 cases, including 80 males and 98 females) and the non-sarcopenia group (185 cases, including 98 males and 87 females). The plasma resistin levels in the sarcopenia group were significantly higher than those in the non-sarcopenia group (7.04±1.63 ng/mL vs. 6.11±1.26 ng/mL, P<0.05). Pearson correlation analysis showed that plasma resistin levels in the elderly population were negatively correlated with grip strength, gait speed, and ASMI (P<0.05). Meanwhile, the Mann-Whitney U test showed no difference in plasma resistin levels between elderly males and females (P>0.05), indicating that resistin levels in the elderly were not influenced by gender. In multivariate logistic regression analysis, after adjusting for confounding factors including age, smoking history, alcohol consumption history, and geriatric nutritional risk index (GNRI), red blood cell count, body mass index (BMI), hypertension, triglycerides, and high-density lipoprotein, the results showed that plasma resistin level remained an independent risk factor for sarcopenia in the elderly (OR=1.663, P<0.01). Stratified logistic regression analysis showed that elevated plasma resistin levels were a risk factor for sarcopenia in older adults in both the hypertension subgroup (OR=1.46, P<0.01) and the non-hypertension subgroup (OR=2.66, P<0.01). However, the interaction test indicated that the effect modification of hypertension status on the association between plasma resistin and sarcopenia did not reach statistical significance (P for interaction=0.078). ROC curve analysis showed that the area under the curve for plasma resistin level in the preliminary screening of sarcopenia in the elderly was 0.712 (P=0.027), with an optimal cut-off value of 5.83 ng/mL, corresponding to a sensitivity of 87.1% and a specificity of 48.1%. Conclusions Plasma resistin levels are significantly elevated in elderly patients with sarcopenia and are independently associated with sarcopenia. It may serve as a preliminary screening biomarker for sarcopenia in the elderly. Howe-ver hypertension status did not show a significant effect modification on this association.

Key words: Sarcopenia, Resistin, Elderly, Biomarkers

CLC Number:

R446
R592

TANG Chaoyi, HUANG Rongrong, QIAO Lu, LI Weixin. Study on plasma resistin as a biomarker for preliminary screening of sarcopenia in elderly adults[J]. Journal of Diagnostics Concepts & Practice, 2026, 25(02): 209-217.

Figures/Tables 7

Table 1

Table 2

Table 3

Figure 1

Figure 2

Figure 3

Figure 4

References 28

[1]	SAYER A A, COOPER R, ARAI H, et al. Sarcopenia[J]. Nat Rev Dis Primers, 2024,10:68.
[2]	YUAN S, LARSSON S C. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences[J]. Metabolism, 2023,144:155533.
[3]	景海蓉, 陈雅雯, 付泓博, 等. 肌少症的血清生物标志物[J]. 中华老年多器官疾病杂志, 2022, 21(8):616-620.
	JING H R, CHEN Y W, FU H B, et al. Serum biomarkers for sarcopenia[J]. Chin J Mult Organ Dis Elderly, 2022, 21(8):616-620.
[4]	ZHOU L, LI J Y, HE P P, et al. Resistin: Potential biomarker and therapeutic target in atherosclerosis[J]. Clin Chim Acta, 2021,512:84-91.
[5]	DEB A, DESHMUKH B, RAMTEKE P, et al. Resistin: A journey from metabolism to cancer[J]. Transl Oncol, 2021, 14(10):101178. doi: 10.1016/j.tranon.2021.101178 URL
[6]	WILHELMSEN A, TSINTZAS K, JONES S W. Recent advances and future avenues in understanding the role of adipose tissue cross talk in mediating skeletal muscle mass and function with ageing[J]. Geroscience, 2021, 43(1):85-110. doi: 10.1007/s11357-021-00322-4 pmid: 33528828
[7]	DE LUIS D, PRIMO D, IZAOLA O, et al. Relationship of circulating resistin levels with muscle mass determined by bioelectrical impedance in females with obesity[J]. Endocrinol Diabetes Nutr, 2023, 70(7):468-475.
[8]	孙蓉媛, 郭丽艳, 王方方, 等. KPS、SMS评分及GNRI对急诊老年脓毒症患者病情程度及28 d死亡的评估价值[J]. 中国老年学杂志, 2025, 45(16):3935-3939.
	SUN R Y, GUO L Y, WANG F F, et al. Evaluation value of KPS, SMS score and GNRI on the severity of illness and 28 day death in elderly patients with sepsis in emergency department[J]. Chin J Gerontol, 2025, 45(16):3935-3939.
[9]	CHEN L K, WOO J, ASSANTACHAI P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012 URL
[10]	邹慧敏, 王遂军. 中国糖尿病诊断标准演变及特殊人群血糖管理[J]. 诊断学理论与实践, 2025, 24(1):14-20.
	ZOU H M, WANG S J. Evolution of diagnosis standards for diabetes in China and blood glucose management for special populations[J]. J Diagn Concepts Pract, 2025, 24(1):14-20.
[11]	CHEN S, HE T, SUN S, et al. Prognostic significance of pre- to postoperative dynamics of sarcopenia for patients with renal cell carcinoma undergoing laparoscopic nephrectomy[J]. Front Surg, 2022,9:871731.
[12]	OZER F F, AKIN S, TASCI İ, et al. Risk of sarcopenia in hospitalized patients and related clinical factors: A multicenter study from Turkey[J]. Eur Geriatr Med, 2021, 12(4):863-870. doi: 10.1007/s41999-021-00499-z pmid: 33866525
[13]	HSU K J, CHIEN K Y, TSAI S C, et al. Effects of exercise alone or in combination with high-protein diet on muscle function, aerobic capacity, and physical function in middle-aged obese adults: A randomized controlled trial[J]. J Nutr Health Aging, 2021, 25(6):727-734. doi: 10.1007/s12603-021-1599-1 pmid: 34179925
[14]	RAGHUPATHY R, MCLEAN R R, KIEL D P, et al. Higher abdominal adiposity is associated with higher lean muscle mass but lower muscle quality in middle-aged and older men and women: The Framingham Heart Study[J]. Aging Clin Exp Res, 2023, 35(7):1477-1485. doi: 10.1007/s40520-023-02427-6 pmid: 37166563
[15]	VAN HOLLEBEKE R B, CUSHMAN M, SCHLUETER E F, et al. Abdominal muscle density is inversely related to adiposity inflammatory mediators[J]. Med Sci Sports Exerc, 2018, 50(7):1495-1501. doi: 10.1249/MSS.0000000000001570 URL
[16]	BOTERO J P, SHIGUEMOTO G E, PRESTES J, et al. Effects of long-term periodized resistance training on body composition, leptin, resistin and muscle strength in elderly post-menopausal women[J]. J Sports Med Phys Fitness, 2013, 53(3):289-294.
[17]	GAO J, DENG M, LI Y, et al. Resistin as a systemic inflammation-related biomarker for sarcopenia in patients with chronic obstructive pulmonary disease[J]. Front Nutr, 2022,9:921399.
[18]	RAVA A, PIHLAK A, KUMS T, et al. Resistin concentration is inversely associated with objectively measured physical activity in healthy older women[J]. Aging Clin Exp Res, 2020, 32(3):475-481. doi: 10.1007/s40520-019-01222-6 pmid: 31115876
[19]	SCHMIDT M, WEIDEMANN A, POSER C, et al. Stimulation of non-canonical NF-κB through lymphotoxin-β-receptor impairs myogenic differentiation and regeneration of skeletal muscle[J]. Front Cell Dev Biol, 2021,9:721543.
[20]	REN Y, ZHAO H, YIN C, et al. Adipokines, hepatokines and myokines: Focus on their role and molecular mechanisms in adipose tissue inflammation[J]. Front Endocrinol, 2022,13:873699.
[21]	MALLARDO M, DANIELE A, MUSUMECI G, et al. A narrative review on adipose tissue and overtraining: Shedding light on the interplay among adipokines, exercise and overtraining[J]. Int J Mol Sci, 2024, 25(7):4089. doi: 10.3390/ijms25074089 URL
[22]	CHEN Z, TAO S, LI X, et al. Resistin destroys mitochondrial biogenesis by inhibiting the PGC-1α/NRF1/TFAM signaling pathway[J]. Biochem Biophys Res Commun, 2018, 504(1):13-18. doi: 10.1016/j.bbrc.2018.08.027 URL
[23]	KWAK M K, BAEK J Y, PARK S J, et al. Higher circula-ting resistin levels linked to increased sarcopenia risk in older adults[J]. J Clin Endocrinol Metab, 2025, 110(9):e2994-e3001. doi: 10.1210/clinem/dgae894 URL
[24]	YU H, ZHU G, WANG D, et al. PI3K/AKT/FOXO3a pathway induces muscle atrophy by ubiquitin-proteasome system and autophagy system in COPD rat model[J]. Cell Biochem Biophys, 2024, 82(2):805-815. doi: 10.1007/s12013-024-01232-w pmid: 38386223
[25]	WANG K, LIU Q, TANG M, et al. Chronic kidney disease-induced muscle atrophy: Molecular mechanisms and promising therapies[J]. Biochem Pharmacol, 2023,208:115407.
[26]	RIZVI A A, RIZZO M. Age-related changes in insulin resistance and muscle mass: Clinical implications in obese older adults[J]. Medicina, 2024, 60(10):1648. doi: 10.3390/medicina60101648 URL
[27]	VOULGARIDOU G, TYROVOLAS S, DETOPOULOU P, et al. Diagnostic criteria and measurement techniques of sarcopenia: A critical evaluation of the up-to-date evidence[J]. Nutrients, 2024, 16(3):436. doi: 10.3390/nu16030436 URL
[28]	VOELKER S N, MICHALOPOULOS N, MAIER A B, et al. Reliability and concurrent validity of the SARC-F and its modified versions: A systematic review and meta-analysis[J]. J Am Med Dir Assoc, 2021, 22(9):1864-1876.e16. doi: 10.1016/j.jamda.2021.05.011 pmid: 34144049

Item	No sarcopenia（n=185）	Sarcopenia（n=178）	P value
Gender
Male(%)	98(52.97)	80(44.94)	0.126
Female(%)	87(47.03)	98(55.06)	0.126
Smoking(%)	30(16.22)	28(15.73)	0.899
Drinking(%)	19(10.27)	16(8.99)	0.679
Hypertension(%)	131(70.81)	96(53.93)	<0.001
Diabetes(%)	71(38.38)	52(29.21)	0.065
Stroke(%)	90(48.65)	93(52.25)	0.864
Fasting blood glucose (mmol/L)	5.40(4.71,6.28)	5.10(4.58,6.07)	0.117
Age(years)	72.06±7.89	74.25±8.54	0.006
Body weight(kg)	65.70（59.50,73.75）	56.00（49.45,68.70）	<0.001
Height(cm)	165.00（160.00,170.00）	164.22（158.00,170.00）	0.268
BMI(kg/m²)	24.20（22.50,26.45）	21.30（19.78,23.23）	<0.001
Grip strength(kg)	18.45±6.45	15.02±5.30	<0.001
Gait speed(m/s)	1.02±0.34	0.89±0.31	0.011
Chair stand(s)	11.91±3.65	13.55±4.31	0.020
ASMI(kg/m²)	7.51±1.25	5.58±0.94	<0.001
GNRI	109.89±9.40	102.81±9.55	<0.001
Resistin(ng/mL)	6.11±1.26	7.04±1.63	<0.001
Erythrocyte (×10¹²/L)	4.72（4.29,5.05）	4.41（4.11,4.77）	<0.001
Leukocyte (×10⁹/L)	5.43（4.57,6.51）	5.3（4.24,6.62）	0.249
Platelet (×10⁹/L)	192.00（152.00,229.00）	194.00（150.25,243.50）	0.420
Hemoglobin (g/L)	145.00（135.00,157.00）	137.5（125.75,147.25）	<0.001
Total protein (g/L)	72.80±6.90	71.20±7.30	0.038
Albumin (g/L)	43.9（40.70,46.70）	43.3（39.4,46.00）	0.084
Globulin (g/L)	29.00（26.25,32.05）	28.15（25.28,31.83）	0.081
Triglyceride (mmol/L)	1.34（1.02,1.82）	1.11（0.87,1.56）	<0.001
HDL-C(mmol/L)	1.11（0.98,1.35）	1.26（1.07,1.55）	<0.001
Total cholesterol (mmol/L)	4.17（3.51,4.91）	4.35（3.55,5.11）	0.239
LDL-C(mmol/L)	2.65（2.18,3.29）	2.69（2.09,3.36）	0.926
Apolipoprotein a (mmol/L)	1.32（1.15,1.56）	1.43（1.22,1.68）	0.060
Serum creatinine (ummol/L)	55.90（62.30,84.35）	67.15（58.18,78.18）	0.050

Item	Grip strength	Gait speed	Chair stand	ASMI	Age	BMI
Resistin
r	-0.192	-0.114	0.102	-0.274	0.108	-0.169
P	<0.001	0.030	0.051	<0.001	0.04	0.01

Model	Variable	β	SE	Wald χ²	OR（95%CI）	P value
1	Resistin	0.533	0.098	29.523	1.704（1.406-2.065）	<0.001
2	Resistin	0.501	0.103	23.803	1.651（1.350-2.019）	<0.001
	Age	0.031	0.016	3.862	1.031（1.000-1.064）	0.049
	BMI	0.288	0.056	26.535	0.749（0.672-0.836）	<0.001
	GNRI	0.019	0.017	1.165	0.981（0.948-1.016）	0.280
	Drinking	0.095	0.554	0.029	0.91（0.307-2.295）	0.864
	Smoking	0.332	0.437	0.574	1.393（0.591-3.283）	0.449
3	Resistin	0.509	0.104	23.938	1.663（1.357-2.039）	<0.001
	Age	0.037	0.016	5.159	1.037（1.005-1.071）	0.023
	BMI	0.285	0.056	25.526	0.752（0.673-0.840）	<0.001
	GNRI	0.021	0.018	1.349	0.980（0.946-1.014）	0.246
	Drinking	0.159	0.563	0.08	0.853（0.283-2.570）	0.777
	Smoking	0.252	0.443	0.323	1.286（1.540-3.064）	0.570
	Hypertension	0.859	0.264	10.578	0.423（0.252-0.711）	0.001
4	Resistin	0.509	0.108	22.324	1.663（1.347-2.054）	<.001
	Age	0.037	0.017	4.918	1.038（1.004-1.072）	0.027
	BMI	0.264	0.061	19.041	0.768（0.682-0.865）	<.001
	GNRI	0.023	0.021	1.209	0.978（0.939-1.018）	0.272
	Drinking	0.037	0.584	0.004	0.964（0.307-3.125）	0.950
	Smoking	0.463	0.425	0.843	1.529（0.617-3.789）	0.359
	Hypertension	0.743	0.273	7.393	0.476（0.279-0.813）	0.007
	Erythrocyte	0.401	0.227	3.116	0.670（0.429-1.045）	0.078
	Triglyceride	0.195	0.106	0.297	0.899（0.614-1.318）	0.586
	HDL-C	1.455	0.42	12.01	4.286（1.882-9.763）	<.001